Suhendan Ekmekcioglu

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24
    Eva G Caudell
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Immunol 168:6041-6. 2002
  2. pmc Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24
    Suhendan Ekmekcioglu
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 362, Houston, TX 77030, USA
    Cytokine 43:34-44. 2008
  3. doi request reprint Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells
    Suhendan Ekmekcioglu
    Department of Melanoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nutr Cancer 63:940-9. 2011
  4. ncbi request reprint Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells
    Suhendan Ekmekcioglu
    Department of Bioimmunotherapy, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 2:9-17. 2003
  5. pmc Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells
    Mingzhong Zheng
    Introgen Therapeutics, 2250 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:3842-51. 2008
  6. ncbi request reprint Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism
    Sunil Chada
    Introgen Therapeutics, Inc, Houston, TX 77030, USA
    Mol Ther 10:1085-95. 2004
  7. ncbi request reprint Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10
    Mingzhong Zheng
    Introgen Therapeutics Inc, 2250 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Immunol Immunother 56:205-15. 2007
  8. pmc Association of activated c-Met with NRAS-mutated human melanomas
    Chandrani Chattopadhyay
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 131:E56-65. 2012
  9. pmc Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma
    Yong Qin
    Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Res 9:1537-50. 2011
  10. pmc Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis
    Elizabeth A Grimm
    Department of Experimental Therapeutics, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Nitric Oxide 19:133-7. 2008

Collaborators

Detail Information

Publications28

  1. ncbi request reprint The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24
    Eva G Caudell
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Immunol 168:6041-6. 2002
    ....
  2. pmc Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24
    Suhendan Ekmekcioglu
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 362, Houston, TX 77030, USA
    Cytokine 43:34-44. 2008
    ..In summary, we described a novel pathway of MDA7/IL-24 regulation of apoptosis in melanoma tumors via endogenous IFN-beta induction followed by IRF regulation and TRAIL/FasL system activation...
  3. doi request reprint Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells
    Suhendan Ekmekcioglu
    Department of Melanoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nutr Cancer 63:940-9. 2011
    ..Based on the responsible molecular mechanisms of Zyflamend, our study highlights the importance of the use of herbal preparations for the prevention and treatment of cancer...
  4. ncbi request reprint Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells
    Suhendan Ekmekcioglu
    Department of Bioimmunotherapy, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 2:9-17. 2003
    ..These studies demonstrate that expression of the MDA-7 tumor suppressor can negatively regulate iNOS expression in malignant melanoma cell lines...
  5. pmc Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells
    Mingzhong Zheng
    Introgen Therapeutics, 2250 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:3842-51. 2008
    ..This study shows that IL-24 can play a significant role in overcoming temozolomide resistance and that the clinical efficacy of temozolomide may be improved by using a biochemotherapy combination with IL-24...
  6. ncbi request reprint Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism
    Sunil Chada
    Introgen Therapeutics, Inc, Houston, TX 77030, USA
    Mol Ther 10:1085-95. 2004
    ..This study defines a tumor-selective cytotoxic bystander role for secreted MDA-7 protein and identifies a novel receptor-mediated, STAT3-independent, and PKR-independent death pathway...
  7. ncbi request reprint Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10
    Mingzhong Zheng
    Introgen Therapeutics Inc, 2250 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Immunol Immunother 56:205-15. 2007
    ....
  8. pmc Association of activated c-Met with NRAS-mutated human melanomas
    Chandrani Chattopadhyay
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 131:E56-65. 2012
    ..On the basis of these experimental results, we propose that c-Met inhibition may be a useful therapeutic strategy for melanomas with NRAS mutations, as well as some tumors with a wt/wt genotype...
  9. pmc Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma
    Yong Qin
    Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Res 9:1537-50. 2011
    ..These results indicate that the endogenous IL-1 system is functional in most human melanoma and interrupting its signaling inhibits the growth of IL-1-positive melanoma cells...
  10. pmc Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis
    Elizabeth A Grimm
    Department of Experimental Therapeutics, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Nitric Oxide 19:133-7. 2008
    ..Our goal is to understand the aberrant biology leading to this curious phenomenon, and to regulate it in favor of patient treatments...
  11. ncbi request reprint Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes
    John B Mumm
    Department of Experimental Therapeutics, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Interferon Cytokine Res 26:877-86. 2006
    ..Thus, we demonstrated that the secreted, glycosylated, dimeric, human IL-24 is immunomodulatory to monocytes and exhibits tumor cell growth inhibition...
  12. ncbi request reprint Tumor iNOS predicts poor survival for stage III melanoma patients
    Suhendan Ekmekcioglu
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 119:861-6. 2006
    ..The ability of iNOS to predict outcomes for these patients may be independent of other known prognostic factors, providing a new molecular marker with significant potential for clinical utility...
  13. ncbi request reprint Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells
    Mingzhong Zheng
    Department of Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Melanoma Res 14:165-71. 2004
    ..Therefore, curcumin should be considered further as a potential therapy for patients with melanoma...
  14. ncbi request reprint Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening
    Yong Qin
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Pigment Cell Melanoma Res 26:97-112. 2013
    ....
  15. ncbi request reprint NO news is not necessarily good news in cancer
    Suhendan Ekmekcioglu
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Cancer Drug Targets 5:103-15. 2005
    ..This balance may serve as an important focal point in determining patient response to therapy. The ability to control this balance could significantly influence outcome...
  16. ncbi request reprint MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family
    Sunil Chada
    Introgen Therapeutics, Inc, 2250 Holcombe Blvd, Houston, TX 77030, USA
    Int Immunopharmacol 4:649-67. 2004
    ..Thus, mda-7 is a unique multifunctional cytokine in the IL-10 family and may have potent antitumor utility in a clinical setting...
  17. pmc Clinical correlates of NRAS and BRAF mutations in primary human melanoma
    Julie A Ellerhorst
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:229-35. 2011
    ..This study was designed to test the hypothesis that primary human cutaneous melanomas harboring mutations in NRAS or BRAF display a more aggressive clinical phenotype than tumors wild type at both loci...
  18. pmc Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy
    Andrew G Sikora
    Department of Melanoma Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 16:1834-44. 2010
    ..We tested the hypothesis that targeted iNOS inhibition would interfere with human melanoma growth and survival in vivo in a preclinical model...
  19. pmc PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells
    Alexis L Stewart
    Department of Research, Introgen Therapeutics, Inc, Houston, Texas 77030, USA
    Mol Med 8:451-61. 2002
    ..Here we investigate in vitro the effects of blocking PI3K signaling using adenoviral-delivered PTEN (Ad-PTEN) in cell lines derived from both early- and late-stage melanoma...
  20. ncbi request reprint IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways
    Wu Guo Deng
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Melanoma Res 21:44-56. 2011
    ....
  21. pmc The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment
    Hong Zhou
    Department of Experimental Therapeutics, UT M D Anderson Cancer Center, Houston, TX, USA
    J Invest Dermatol 133:1052-62. 2013
    ..We conclude that Fn14 is a therapeutic target in melanoma and the hSGZ construct appears to warrant further development as a therapeutic agent against Fn14-positive melanoma...
  22. pmc The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10
    Keiji Tanese
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 131:891-901. 2012
    ..Inhibiting NO induces an antitumorigenic environment, and thus, iNOS should be considered to be an important therapeutic target in melanoma...
  23. pmc Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment
    Cindy S Hwang
    School of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Melanoma Res 18:241-5. 2008
    ..A better understanding of the AKT and mitogen-activated protein kinase pathways is needed to optimize the clinical benefit of targeted therapy, such as imatinib...
  24. ncbi request reprint Implications of tissue transglutaminase expression in malignant melanoma
    Jansina Y Fok
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 5:1493-503. 2006
    ..Overall, our results suggest that TG2 expression contributes to the development of chemoresistance in malignant melanoma cells by exploiting integrin-mediated cell survival signaling pathways...
  25. ncbi request reprint A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide
    Ann Marie Simeone
    Department of Bioimmunotherapy, Sections of Immunobiology and Drug Carriers, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 1:1009-17. 2002
    ..When combined with 4-HPR, IFN-gamma and TAM enhanced NOSII expression. Thus, we have identified a novel mechanism by which 4-HPR induces apoptosis in breast cancer cells, i.e., by increasing NOS expression to induce NO production...
  26. ncbi request reprint Loss of MDA-7 expression with progression of melanoma
    Julie A Ellerhorst
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    J Clin Oncol 20:1069-74. 2002
    ..As a secondary objective, we analyzed MDA-7 protein expression in primary melanomas for correlation with predictors of outcome and with survival...
  27. pmc Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma
    Jahan S Khalili
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Cancer Res 18:5329-40. 2012
    ....
  28. ncbi request reprint Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients
    Alex W Tong
    Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA
    Mol Ther 11:160-72. 2005
    ..Intratumoral delivery of INGN 241 induced apoptosis in a large volume of tumor and elicited tumor-regulatory and immune-activating events that are consistent with the preclinical features of MDA-7/IL-24...